In resected, stage I–III colon cancer or following neoadjuvant therapy and while on WW in LARC, plasma ctDNA offers superior sensitivity to CEA and median lead times of up to 11 months for radiographic detection of recurrence [23,28,62]. This evidence concerns the gene CEACAM5 and colonic neoplasm.